Close Menu

NEW YORK – Fluidigm reported on Tuesday that its preliminary fourth quarter revenues of 2019 are expected to be $32.0 to $32.4 million, which is at the upper end of the company’s guidance range of $29 to $32 million. In its year ago period, the firm posted revenues of $32.3 million.

On average, analysts expect the South-San Francisco-based company to report $30.2 million in revenues for Q4. During the recently completed quarter, it had mass cytometry annualized consumables pull-through of about $72,000. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

A German shepherd called Nala has had her genome sequenced.

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.